Flamel Technologies SA is a specialty pharmaceutical company focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs.
The Company’s versatile, proprietary drug delivery platforms may be used to solve threshold issues for development of insoluble molecules, biologics that are prone to aggregation, and poorly stable chemical and biological drugs:
- Micropump® platform (oral drugs) for the formulation and the controlled release of chemical drugs that are best absorbed in the small intestine.
- Trigger Lock™ may be used to create controlled release, tamper resistant formulations of narcotics and other drugs susceptible to abuse.
- LiquiTime® allows the extended release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly.
- Medusa™ platform (injectable drugs) for the formulation and/or the extended release of biologics (including proteins, antibodies, and peptides) as well as small molecules.